The strong one-year data significantly de-risk the Revita pivotal trial. Traders should position for the early Q4 2026 topline readout and potential De Novo submission. Monitor for any competitive developments in the post-GLP-1 weight maintenance space.
Price Chart
Executive Summary
Fractyl Health reported positive one-year results from the REMAIN-1 Midpoint Cohort for its Revita DMR System, showing a single procedure reduced weight regain by ~40% vs sham after GLP-1 discontinuation. In patients receiving complete duodenal ablation, 81% of GLP-1-induced weight loss was retained at one year vs 48% with sham, with a responder rate of 73-91% against the FDA-mandated 50% performance goal. The safety profile was benign with no device-related serious adverse events. These data de-risk the ongoing pivotal trial (N=315, topline expected early Q4 2026) and support a potential FDA De Novo submission in late Q4 2026.
Key Facts
- Single Revita procedure reduced weight regain by ~40% vs sham at one year in mITT population (7.8% vs 13.0% regain)
- Complete duodenal ablation (>14 cm) cohort retained 81% of GLP-1 weight loss vs 48% sham
- Optimized population (complete ablation + ≥17.5% run-in loss) retained 84% vs 46% sham
- Responder rate (≥5% TBWL maintained at 1 year) was 73% in mITT and 91% in complete ablation cohort
- No device- or procedure-related serious adverse events; TEAE rates comparable to sham (24% vs 25%)
- Pivotal cohort fully randomized (N=315); topline 6-month data expected early Q4 2026
- Potential FDA De Novo submission in late Q4 2026; $63M cash on hand funds through pivotal readout
Financial Impact
Clinical data shows up to 84% weight loss retention vs 46% sham; responder rate 73-91% against FDA-mandated 50% goal. No revenue reported; pipeline value increased.
Risk Factors
- Pivotal trial may fail to replicate these exploratory results
- FDA may not accept or approve De Novo application
- Competition from other weight maintenance therapies (GLP-1s, other devices)
- Company has no revenue and relies on capital markets; cash runway only into early 2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-303948 |
| Document: guts-ex99_2.htm | 0001193125-26-303948 |
| Document: guts-ex99_1.htm | 0001193125-26-303948 |
| Document: 0001193125-26-303948-index-headers.html | 0001193125-26-303948 |
| Document: 0001193125-26-303948-index.html | 0001193125-26-303948 |
| Document: 0001193125-26-303948.txt | 0001193125-26-303948 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $1.13 | awaiting T+5 | — | $1.08 (−4.42%) |
Oct 16, 2026 10d ago | 8-K | $1.55 $1.08 | ▼ −30.32% | ▼ −30.42% | $1.08 (−30.32%) |
Oct 13, 2026 12d ago | SC 13G | $4.03 $1.33 | ▼ −66.96% | ▼ −65.80% | $1.08 (−73.17%) |
Aug 10, 2026 10w ago | 8-K | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Aug 10, 2026 10w ago | Press Release | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Jul 15, 2026 14w ago | 8-K | $0.9100 $0.7580 | ▼ −16.70% | ▼ −15.72% | $1.08 (+18.68%) |
Jun 12, 2026 19w ago | Institutional Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Insider Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.7239 $0.8500 | ▲ +17.42% | ▲ +16.99% | $1.08 (+49.19%) |
Jun 4, 2026 20w ago | 8-K | $0.7340 $0.7240 | ▼ −1.36% | ▲ +1.19% | $1.08 (+47.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers